Reactive oxygen species imbalance in atherosclerosis: Biomarker phenotyping, residual risk, and a translational framework for precision prevention
Journal of Clinical and Translational Research · 03.08.2026 · 12 (5) · 026250058
DOI: 10.36922/jctr026250058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Translational Research, online erschienen am 03.08.2026. Verfasst von Yasser M. Esmaeil und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Atherosclerotic cardiovascular disease (ASCVD) leaves substantial residual risk despite intensive low-density lipoprotein-cholesterol lowering and anti-inflammatory therapy. Reactive oxygen species (ROS) have long been implicated, yet neutral broad-antioxidant trials left unclear which dimensions of ROS imbalance are causal, clinically informative, and therapeutically tractable.
Aim
To critically appraise ROS imbalance in atherosclerosis through a plausibility–association–utility hierarchy and to propose a staged framework for precision cardiovascular prevention.
Methods
We synthesized mechanistic, biomarker, and translational evidence from targeted PubMed/MEDLINE, Embase, and Cochrane searches (January 2000–February 2026), combining terms for ROS, oxidative stress, atherosclerosis, oxidative biomarkers, and residual cardiovascular risk, with citation chaining. Mass-spectrometry biomarker work, prospective cohorts, and randomized trials received greater interpretive weight. Systematic-review procedures were not applied.
Results
Compartmentalized, source-specific ROS imbalance contributes to endothelial dysfunction, lipoprotein oxidation, inflammatory amplification, and plaque progression, particularly in high-risk cardiometabolic phenotypes. Human biomarker data are predominantly observational, assay standardization is incomplete, and risk-reclassification evidence is limited. F2-isoprostanes are a relatively mature lipid-peroxidation marker better suited to trial enrichment than treatment selection.
Conclusion
Oxidative biomarkers are defensibly used for trial enrichment but not individual treatment selection. A staged precision-prevention agenda should test source-selective interventions in biomarker-enriched cohorts using vascular and mechanistic endpoints before large outcome trials. Relevance for Patients: Adults whose cardiovascular risk remains high despite cholesterol-lowering and anti-inflammatory treatment—including those with diabetes, kidney disease, smoking, obesity, or recurrent events—may eventually benefit if oxidative stress tests can identify who remains vulnerable and guide targeted prevention.
Zitieren
APA
Esmaeil, Y. M., Nurillaeva, M., Khan, A., & Wiesner, M. (2026). Reactive oxygen species imbalance in atherosclerosis: Biomarker phenotyping, residual risk, and a translational framework for precision prevention. Journal of Clinical and Translational Research, 12(5), 026250058. https://doi.org/10.36922/jctr026250058
Vancouver
Esmaeil YM, Nurillaeva M, Khan A, Wiesner M. Reactive oxygen species imbalance in atherosclerosis: Biomarker phenotyping, residual risk, and a translational framework for precision prevention. Journal of Clinical and Translational Research. 2026;12(5):026250058. doi:10.36922/jctr026250058
BibTeX
@article{Esmaeil2026,
author = {Esmaeil, Yasser M. and Nurillaeva, Marjona and Khan, Aamir and Wiesner, Matthew},
title = {Reactive oxygen species imbalance in atherosclerosis: Biomarker phenotyping, residual risk, and a translational framework for precision prevention},
journal = {Journal of Clinical and Translational Research},
year = {2026},
volume = {12},
number = {5},
pages = {026250058},
doi = {10.36922/jctr026250058}
}
EUVIMED